Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
24.62
Dollar change
+0.33
Percentage change
1.36
%
IndexRUT P/E- EPS (ttm)-3.20 Insider Own15.96% Shs Outstand69.15M Perf Week15.42%
Market Cap1.70B Forward P/E- EPS next Y-4.13 Insider Trans-1.28% Shs Float58.12M Perf Month21.28%
Income-179.27M PEG- EPS next Q-0.83 Inst Own99.14% Short Float12.83% Perf Quarter-10.05%
Sales0.00M P/S- EPS this Y-29.12% Inst Trans15.69% Short Ratio8.16 Perf Half Y24.60%
Book/sh12.24 P/B2.01 EPS next Y-10.61% ROA-28.43% Short Interest7.46M Perf Year-56.72%
Cash/sh13.07 P/C1.88 EPS next 5Y- ROE-31.11% 52W Range11.25 - 58.38 Perf YTD5.44%
Dividend Est.- P/FCF- EPS past 5Y1.03% ROI-20.33% 52W High-57.83% Beta-0.29
Dividend TTM- Quick Ratio30.12 Sales past 5Y0.00% Gross Margin- 52W Low118.84% ATR (14)1.48
Dividend Ex-Date- Current Ratio30.12 EPS Y/Y TTM-17.00% Oper. Margin0.00% RSI (14)70.10 Volatility8.32% 6.84%
Employees56 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.22 Target Price46.56
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q-63.47% Payout- Rel Volume0.64 Prev Close24.29
Sales Surprise- EPS Surprise0.24% Sales Q/Q- EarningsMay 10 BMO Avg Volume913.83K Price24.62
SMA2020.28% SMA5017.90% SMA200-1.17% Trades Volume583,963 Change1.36%
Date Action Analyst Rating Change Price Target Change
Apr-22-24Resumed BofA Securities Neutral $30
Sep-19-23Initiated Cantor Fitzgerald Overweight $69
Aug-28-23Initiated UBS Buy $83
Jan-27-23Upgrade Morgan Stanley Equal-Weight → Overweight $40 → $65
Sep-14-22Upgrade Evercore ISI In-line → Outperform $10 → $50
Oct-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $27
Sep-10-21Initiated BofA Securities Buy $40
Feb-26-21Initiated Guggenheim Buy $54
Sep-10-20Initiated Morgan Stanley Overweight $70
Jul-20-20Reiterated H.C. Wainwright Buy $45 → $62
Jun-13-24 03:57PM
09:00AM
Jun-11-24 07:00AM
Jun-10-24 10:14AM
Jun-08-24 08:15AM
10:39AM Loading…
Jun-06-24 10:39AM
Jun-03-24 09:57AM
May-30-24 09:16PM
May-29-24 07:00AM
May-23-24 02:12PM
May-15-24 09:26AM
May-12-24 09:01PM
May-10-24 01:54PM
07:45AM
07:00AM
07:00AM Loading…
May-08-24 07:00AM
Apr-30-24 08:00AM
Apr-22-24 06:00AM
Mar-20-24 01:32PM
12:58PM
Mar-18-24 07:00AM
Mar-08-24 04:02PM
Mar-07-24 04:01PM
Mar-06-24 11:54PM
Mar-05-24 09:13PM
02:12PM
Mar-04-24 04:21PM
04:04PM
12:30PM
11:59AM
09:23AM Loading…
09:23AM
06:22AM
06:09AM
06:00AM
04:00AM
Mar-01-24 09:55AM
Feb-29-24 08:00AM
07:00AM
Feb-06-24 10:48AM
Feb-05-24 09:55AM
Jan-30-24 09:40AM
Jan-03-24 08:15AM
Dec-18-23 07:00AM
Dec-13-23 03:06AM
Dec-05-23 01:34PM
12:36PM
Nov-14-23 07:21PM
Nov-13-23 07:00AM
Nov-10-23 08:57AM
Nov-08-23 07:00AM
Oct-17-23 04:05PM
Oct-12-23 04:38PM
08:24AM
Oct-11-23 05:35PM
11:11AM
Oct-10-23 04:13PM
04:03PM
12:10PM
11:44AM
10:37AM
09:29AM
07:15AM
07:00AM
Oct-09-23 04:05PM
Oct-05-23 07:01AM
Oct-04-23 08:00AM
Sep-29-23 12:43PM
Sep-27-23 09:24PM
Sep-14-23 07:56AM
Aug-31-23 07:00AM
Aug-28-23 07:00AM
Aug-11-23 06:00AM
Jul-11-23 09:02AM
Jul-10-23 09:32AM
09:29AM
08:58AM
Jul-07-23 08:00AM
07:46AM
Jul-03-23 11:20AM
10:25AM
Jul-01-23 09:00AM
Jun-29-23 10:04AM
09:59AM
09:18AM
Jun-28-23 10:53AM
Jun-27-23 01:47PM
Jun-26-23 11:23AM
11:15AM
10:36AM
08:50AM
08:21AM
06:41AM
Jun-23-23 10:50AM
09:15AM
07:00AM
Jun-22-23 09:18AM
Jun-21-23 03:21PM
10:46AM
Jun-20-23 08:54AM
Jun-19-23 10:28AM
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cheng AndrewPresident and CEOJun 11 '24Sale22.647,894178,728581,553Jun 13 06:01 PM
White William RichardChief Financial OfficerJun 11 '24Sale22.642,83164,09446,799Jun 13 06:09 PM
Yale CatrionaChief Development OfficerJun 11 '24Sale22.642,82563,96174,867Jun 13 06:11 PM
Young JonathanChief Operating OfficerJun 11 '24Sale22.642,51656,965250,790Jun 13 06:13 PM
Rolph TimothyChief Scientific OfficerJun 11 '24Sale22.642,38053,886180,178Jun 13 06:06 PM
Lamy PatrickSenior VP, Commercial StrategyJun 11 '24Sale22.6456912,88318,562Jun 13 06:04 PM
Young JonathanChief Operating OfficerJun 03 '24Sale19.295,00096,440253,306Jun 05 05:05 PM
Young JonathanChief Operating OfficerMay 01 '24Sale20.155,000100,750258,306May 02 09:07 PM
Young JonathanChief Operating OfficerApr 01 '24Sale24.385,000121,913263,306Apr 03 06:55 PM
Cheng AndrewPresident and CEOMar 13 '24Sale28.331,96955,782589,447Mar 15 04:43 PM
White William RichardChief Financial OfficerMar 13 '24Sale28.3372420,51149,630Mar 15 04:44 PM
Yale CatrionaChief Development OfficerMar 13 '24Sale28.3372320,48377,692Mar 15 04:45 PM
Young JonathanChief Operating OfficerMar 13 '24Sale28.3365118,443268,306Mar 15 04:42 PM
Rolph TimothyChief Scientific OfficerMar 13 '24Sale28.3361917,536182,558Mar 15 04:42 PM
Cheng AndrewPresident and CEOMar 04 '24Option Exercise17.1775,0001,288,062666,416Mar 06 08:14 PM
Yale CatrionaChief Development OfficerMar 04 '24Option Exercise13.9620,646288,12499,061Mar 06 08:13 PM
Cheng AndrewPresident and CEOMar 04 '24Sale32.8775,0002,465,063591,416Mar 06 08:14 PM
Yale CatrionaChief Development OfficerMar 04 '24Sale35.4920,646732,72778,415Mar 06 08:13 PM
Young JonathanChief Operating OfficerMar 01 '24Option Exercise0.6183,32151,242268,957Mar 05 05:16 PM
Cheng AndrewPresident and CEOJan 02 '24Option Exercise0.6140,00024,600590,911Jan 03 05:00 PM
Young JonathanChief Operating OfficerDec 27 '23Option Exercise6.365,41434,433190,545Dec 29 08:30 PM
Young JonathanChief Operating OfficerDec 27 '23Sale24.005,414129,936185,131Dec 29 08:30 PM
Cheng AndrewPresident and CEODec 14 '23Sale20.761,62833,797550,911Dec 18 08:37 PM
White William RichardChief Financial OfficerDec 14 '23Sale20.7661112,68450,354Dec 18 08:40 PM
Yale CatrionaChief Development OfficerDec 14 '23Sale20.7659712,39477,910Dec 18 08:49 PM
Young JonathanChief Operating OfficerDec 14 '23Sale20.7654311,273185,131Dec 18 08:39 PM
Rolph TimothyChief Scientific OfficerDec 14 '23Sale20.7651410,671182,672Dec 18 08:29 PM
Cheng AndrewPresident and CEODec 11 '23Option Exercise6.367,40547,096559,944Dec 11 08:59 PM
Cheng AndrewPresident and CEODec 11 '23Sale20.027,405148,273552,539Dec 11 08:59 PM
Cheng AndrewPresident and CEODec 08 '23Option Exercise6.3612,87381,872473,871Dec 11 08:59 PM
Graham G. WalmsleyDirectorDec 08 '23Buy19.83100,0001,982,940800,000Dec 11 09:06 PM
Cheng AndrewPresident and CEODec 08 '23Sale20.0112,873257,571460,998Dec 11 08:59 PM
Cheng AndrewPresident and CEODec 07 '23Option Exercise6.366,70042,612467,698Dec 11 08:59 PM
Cheng AndrewPresident and CEODec 07 '23Sale20.026,700134,125460,998Dec 11 08:59 PM
Graham G. WalmsleyDirectorDec 01 '23Buy16.9950,000849,730700,000Dec 05 08:37 AM
Graham G. WalmsleyDirectorNov 30 '23Buy16.9050,000844,835650,000Dec 05 08:37 AM
Young JonathanChief Operating OfficerNov 17 '23Sale14.6830,000440,259153,177Nov 21 05:30 PM
Cheng AndrewPresident and CEOOct 02 '23Option Exercise6.3625,000159,000485,998Oct 04 08:41 PM
Young JonathanChief Operating OfficerOct 02 '23Option Exercise21.1049010,339183,667Oct 04 08:33 PM
Cheng AndrewPresident and CEOOct 02 '23Sale47.9125,0001,197,827460,998Oct 04 08:41 PM
Young JonathanChief Operating OfficerOct 02 '23Sale51.1049025,039183,177Oct 04 08:33 PM
Yale CatrionaChief Development OfficerSep 21 '23Option Exercise6.365,00031,80051,010Sep 25 08:31 PM
Yale CatrionaChief Development OfficerSep 21 '23Sale48.075,000240,35646,010Sep 25 08:31 PM
Graham G. WalmsleyDirectorSep 19 '23Buy26.00400,00010,400,000400,000May 23 09:55 PM
Cheng AndrewPresident and CEOSep 13 '23Sale50.341,68284,672460,998Sep 25 08:36 PM
White William RichardChief Financial OfficerSep 13 '23Sale50.3463231,81518,468Sep 25 08:31 PM
Yale CatrionaChief Development OfficerSep 13 '23Sale50.3461731,06046,010Sep 25 08:31 PM
Young JonathanChief Operating OfficerSep 13 '23Sale50.3456228,291183,177Sep 25 08:28 PM
Rolph TimothyChief Scientific OfficerSep 13 '23Sale50.3453126,731150,689Sep 25 08:30 PM
Cheng AndrewPresident and CEOSep 01 '23Option Exercise6.3625,000159,000487,680Sep 18 06:48 PM
Cheng AndrewPresident and CEOSep 01 '23Sale49.7725,0001,244,248462,680Sep 18 06:48 PM
Cheng AndrewPresident and CEOAug 30 '23Option Exercise0.6115,0009,225462,680Aug 30 07:04 PM
Yale CatrionaChief Development OfficerAug 28 '23Option Exercise6.365,74536,53852,372Aug 30 07:04 PM
Yale CatrionaChief Development OfficerAug 28 '23Sale49.995,745287,19146,627Aug 30 07:04 PM
Graham G. WalmsleyDirectorAug 08 '23Buy42.0625,0001,051,475600,000Aug 10 04:46 PM
Cheng AndrewPresident and CEOAug 01 '23Option Exercise6.3625,000159,000472,680Aug 03 04:13 PM
Graham G. WalmsleyDirectorAug 01 '23Buy43.2625,0001,081,525575,000Aug 01 07:52 PM
Cheng AndrewPresident and CEOAug 01 '23Sale43.1525,0001,078,867447,680Aug 03 04:13 PM
Graham G. WalmsleyDirectorJul 28 '23Buy42.6930,0001,280,709550,000Aug 01 07:52 PM
Cheng AndrewPresident and CEOJul 03 '23Option Exercise6.3625,000159,000472,680Jul 06 08:44 PM
Cheng AndrewPresident and CEOJul 03 '23Sale44.8825,0001,122,041447,680Jul 06 08:44 PM
Cheng AndrewPresident and CEOJun 27 '23Option Exercise0.6140,00024,600447,680Jun 27 07:12 PM
Yale CatrionaChief Development OfficerJun 23 '23Sale50.7611,000558,36046,627Jun 23 08:06 PM
Yale CatrionaChief Development OfficerJun 22 '23Sale52.1811,000573,93557,627Jun 23 08:06 PM
Yale CatrionaChief Development OfficerJun 21 '23Sale52.2611,349593,09568,627Jun 23 08:06 PM
White William RichardChief Financial OfficerJun 20 '23Option Exercise7.0117,500122,65839,877Jun 22 05:20 PM
White William RichardChief Financial OfficerJun 20 '23Sale55.0020,7771,142,73519,100Jun 22 05:20 PM
Heyman Tomas J.DirectorJun 16 '23Option Exercise25.0426,000651,04026,000Jun 21 05:54 PM
Henderson JaneDirectorJun 16 '23Option Exercise7.0140,000280,40040,000Jun 21 05:47 PM
Rolph TimothyChief Scientific OfficerJun 16 '23Option Exercise0.6140,00024,400229,420Jun 21 05:46 PM
Rolph TimothyChief Scientific OfficerJun 16 '23Sale54.7878,2004,284,066151,220Jun 21 05:46 PM
Henderson JaneDirectorJun 16 '23Sale54.1740,0002,166,6850Jun 21 05:47 PM
Heyman Tomas J.DirectorJun 16 '23Sale54.6726,0001,421,5290Jun 21 05:54 PM